8-K: Cognition Therapeutics Reports Positive Phase 2 Results for Zervimesine in Alzheimer's and Lewy Body Dementia

Cognition Therapeutics' zervimesine shows promising efficacy and safety results in Phase 2 trials for both Alzheimer's disease and dementia with Lewy bodies, positioning it as a potential first-in-class treatment.

Summary

• Cognition Therapeutics is developing zervimesine, a first-in-class oligomer antagonist, for neurodegenerative diseases.
• Zervimesine has shown consistent efficacy in both Alzheimer's disease and dementia with Lewy bodies (DLB) studies.
• The drug has a well-tolerated safety profile, with no unexpected amyloid-related imaging abnormalities (ARIA).
• It is administered orally once daily, eliminating the need for IV therapy or imaging surveillance.
• In the Phase 2 SHIMMER study for DLB, zervimesine demonstrated strong responses across behavioral, functional, cognitive, and movement measures.
• The company has robust intellectual property covering the platform and compounds, including zervimesine, through 2040 with patent term extension.
• The SHIMMER study enrolled 130 participants across 31 sites and was partially funded by a $30 million National Institute on Aging (NIA) grant.
• The SHINE study in Alzheimer's disease enrolled 153 participants and was partially funded by a $31 million NIA grant.
• A subgroup analysis of the SHINE study showed a significant cognitive benefit in participants with lower plasma p-tau217 levels.
• The company has ongoing studies, including the START study in early Alzheimer's disease with approximately 540 participants and the MAGNIFY study in geographic atrophy with approximately 243 participants.
• As of September 30, 2024, the company has $22 million in cash and cash equivalents and $53.6 million in remaining grant funding.

Sentiment

Score: 8

Explanation: The document presents very positive results from Phase 2 trials, highlighting significant efficacy and a favorable safety profile for zervimesine. The company also has strong intellectual property and substantial grant funding, which are all positive indicators. The ongoing studies and future plans are also promising. However, there are some risks and uncertainties associated with clinical trials and regulatory approvals, which prevent a perfect score.

Positives

• Zervimesine has shown consistent efficacy in both Alzheimer's disease and DLB.
• The drug has a well-tolerated safety profile with no unexpected ARIA.
• Oral, once-daily administration is convenient for patients.
• Strong responses were observed across multiple symptom domains in the SHIMMER study for DLB.
• The company has robust intellectual property protection for zervimesine.
• Significant cognitive benefits were observed in a subgroup of Alzheimer's patients with lower p-tau217 levels.
• Ongoing studies are expanding into related patient populations.
• The company has secured substantial grant funding for its research.

Negatives

• Some participants in the SHIMMER study experienced elevated liver function tests (LFTs).
• The 300mg dose group in the SHINE study had more discontinuations and liver enzyme elevations.
• The company has used approximately $117.4 million of its grant funding.

Risks

• The company's ability to successfully advance product candidates through development activities, preclinical studies, and clinical trials is subject to risk.
• Uncertainties exist in the results of preliminary data and earlier-stage clinical trials being predictive of later-stage trials.
• The timing, scope, and likelihood of regulatory filings and approvals are uncertain.
• The company faces competition and must secure new and retain existing grant funding.
• The company's estimates of expenses and profitability are subject to change.
• The company's ability to defend its intellectual property is a risk.
• Ongoing global and regional conflicts and the impact of the COVID-19 pandemic could affect the business.

Future Outlook

The company plans to have an end-of-Phase 2 meeting with the FDA to establish a protocol for a Phase 3 trial in mild-to-moderate Alzheimer's disease, focusing on a population defined by plasma p-tau217 levels. They will also assess the optimal plasma p-tau217 cut-point for future studies.

Management Comments

• The company believes zervimesine has a distinct mechanism of action as a ligand of the TMEM97 (sigma-2) receptor.
• Management highlights the potential of zervimesine as a first-to-market treatment for dementia with Lewy bodies.
• The company is focused on advancing zervimesine through clinical development and regulatory approvals.

Industry Context

This announcement is significant as it presents a potential new treatment approach for Alzheimer's disease and dementia with Lewy bodies, both of which have limited effective therapies. The focus on oligomer antagonism and the use of p-tau217 as a biomarker are aligned with current research trends in the neurodegenerative disease field. The company is also exploring combination therapies with monoclonal antibodies, which is a growing area of interest.

Comparison to Industry Standards

• The magnitude of ADAS-Cog 11 decline at 6 months in the SHINE study was similar to that of approved monoclonal antibodies (MAbs) for Alzheimer's disease, suggesting comparable efficacy.
• The company's focus on a subgroup of patients with lower p-tau217 levels aligns with recent findings that these patients may respond better to amyloid-based therapies, as seen with Donanemab in the TRAILBLAZER 2 study.
• The SHIMMER study's results in DLB are notable as there are currently no approved disease-modifying therapies for this condition, making zervimesine a potential first-in-class treatment.
• The ongoing START study, which allows lecanemab as background therapy, is innovative and could provide valuable insights into combination therapies for early Alzheimer's disease.
• The MAGNIFY trial in geographic atrophy is also significant as there are limited treatment options for this condition, and an oral drug would be a major advancement.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and potential market opportunities.
• Patients with Alzheimer's disease and DLB may have a new treatment option.
• Caregivers of patients with these conditions may experience reduced burden.
• Employees may benefit from the company's growth and success.
• Suppliers and partners may benefit from increased business opportunities.

Next Steps

• The company will have an end-of-Phase 2 meeting with the FDA to establish a protocol for a Phase 3 trial in mild-to-moderate Alzheimer's disease.
• The company will assess the optimal plasma p-tau217 cut-point for future studies.
• The company will continue enrolling participants in the START and MAGNIFY studies.

Key Dates

Keywords

zervimesine, Alzheimer's disease, dementia with Lewy bodies, oligomer antagonist, neurodegenerative diseases, clinical trials, p-tau217, cognitive decline, safety profile, grant funding